214 related articles for article (PubMed ID: 30929538)
1. Doxorubicin-loaded red blood cells reduced cardiac toxicity and preserved anticancer activity.
Lucas A; Lam D; Cabrales P
Drug Deliv; 2019 Dec; 26(1):433-442. PubMed ID: 30929538
[TBL] [Abstract][Full Text] [Related]
2. Enhanced anti-tumor efficacy and reduced cardiotoxicity of doxorubicin delivered in a novel plant virus nanoparticle.
Alemzadeh E; Dehshahri A; Dehghanian AR; Afsharifar A; Behjatnia AA; Izadpanah K; Ahmadi F
Colloids Surf B Biointerfaces; 2019 Feb; 174():80-86. PubMed ID: 30445253
[TBL] [Abstract][Full Text] [Related]
3. Improved antitumor activity and reduced toxicity of doxorubicin encapsulated in poly(ε-caprolactone) nanoparticles in lung and breast cancer treatment: An in vitro and in vivo study.
Cabeza L; Ortiz R; Prados J; Delgado ÁV; Martín-Villena MJ; Clares B; Perazzoli G; Entrena JM; Melguizo C; Arias JL
Eur J Pharm Sci; 2017 May; 102():24-34. PubMed ID: 28219748
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Evaluation of an Epidermal Growth Factor Receptor-Targeted Doxorubicin-Peptide Conjugate: Toxicity, Biodistribution, and Efficacy in Mice.
Yang F; Ai W; Jiang F; Liu X; Huang Z; Ai S
J Pharm Sci; 2016 Feb; 105(2):639-649. PubMed ID: 26869425
[TBL] [Abstract][Full Text] [Related]
5. Quantification of DOX bioavailability in biological samples of mice by sensitive and precise HPLC assay.
Zhang C; Wu Y; Dong Y; Xu H; Zhao L
Pharm Biol; 2016; 54(1):55-61. PubMed ID: 25880143
[TBL] [Abstract][Full Text] [Related]
6. [Targeting therapy of magnetic doxorubicin liposome in nude mice bearing colon cancer].
Zhou PH; Yao LQ; Qin XY; Shen XZ; Liu YS; Lu WY; Yao M
Zhonghua Yi Xue Za Zhi; 2003 Dec; 83(23):2073-6. PubMed ID: 14703420
[TBL] [Abstract][Full Text] [Related]
7. Lectin-Mediated pH-Sensitive Doxorubicin Prodrug for Pre-Targeted Chemotherapy of Colorectal Cancer with Enhanced Efficacy and Reduced Side Effects.
Yao M; Ma X; Zhang X; Shi L; Liu T; Liang X; Zhao H; Li X; Li L; Gao H; Jia B; Wang F
Theranostics; 2019; 9(3):747-760. PubMed ID: 30809306
[TBL] [Abstract][Full Text] [Related]
8. Extracellular vesicles: Natural liver-accumulating drug delivery vehicles for the treatment of liver diseases.
Zhang G; Huang X; Xiu H; Sun Y; Chen J; Cheng G; Song Z; Peng Y; Shen Y; Wang J; Cai Z
J Extracell Vesicles; 2020 Dec; 10(2):e12030. PubMed ID: 33335695
[TBL] [Abstract][Full Text] [Related]
9. A folate modified pH sensitive targeted polymeric micelle alleviated systemic toxicity of doxorubicin (DOX) in multi-drug resistant tumor bearing mice.
Li X; Yang X; Lin Z; Wang D; Mei D; He B; Wang X; Wang X; Zhang Q; Gao W
Eur J Pharm Sci; 2015 Aug; 76():95-101. PubMed ID: 25917524
[TBL] [Abstract][Full Text] [Related]
10. Toxicological study of a new doxorubicin-loaded pH-sensitive liposome: A preclinical approach.
de Oliveira Silva J; Miranda SEM; Leite EA; de Paula Sabino A; Borges KBG; Cardoso VN; Cassali GD; Guimarães AG; Oliveira MC; de Barros ALB
Toxicol Appl Pharmacol; 2018 Aug; 352():162-169. PubMed ID: 29864484
[TBL] [Abstract][Full Text] [Related]
11. Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248).
Mosure KW; Henderson AJ; Klunk LJ; Knipe JO
Cancer Chemother Pharmacol; 1997; 40(3):251-8. PubMed ID: 9219510
[TBL] [Abstract][Full Text] [Related]
12. In vivo distribution and antitumor activity of doxorubicin-loaded N-isopropylacrylamide-co-methacrylic acid coated mesoporous silica nanoparticles and safety evaluation.
Chen Y; Yang W; Chang B; Hu H; Fang X; Sha X
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):406-12. PubMed ID: 23816639
[TBL] [Abstract][Full Text] [Related]
13. Lipoic acid-derived cross-linked liposomes for reduction-responsive delivery of anticancer drug.
Ling L; Ismail M; Du Y; Yao C; Li X
Int J Pharm; 2019 Apr; 560():246-260. PubMed ID: 30769133
[TBL] [Abstract][Full Text] [Related]
14. Vitamin E-based micelles enhance the anticancer activity of doxorubicin.
Danhier F; Kouhé TT; Duhem N; Ucakar B; Staub A; Draoui N; Feron O; Préat V
Int J Pharm; 2014 Dec; 476(1-2):9-15. PubMed ID: 25245548
[TBL] [Abstract][Full Text] [Related]
15. Enhanced antitumor efficacy of doxorubicin-encapsulated halloysite nanotubes.
Li K; Zhang Y; Chen M; Hu Y; Jiang W; Zhou L; Li S; Xu M; Zhao Q; Wan R
Int J Nanomedicine; 2018; 13():19-30. PubMed ID: 29296083
[TBL] [Abstract][Full Text] [Related]
16. Enriching lipid nanovesicles with short-chain glucosylceramide improves doxorubicin delivery and efficacy in solid tumors.
van Lummel M; van Blitterswijk WJ; Vink SR; Veldman RJ; van der Valk MA; Schipper D; Dicheva BM; Eggermont AM; ten Hagen TL; Verheij M; Koning GA
FASEB J; 2011 Jan; 25(1):280-9. PubMed ID: 20876209
[TBL] [Abstract][Full Text] [Related]
17. Enhanced antitumor efficacy and reduced systemic toxicity of sulfatide-containing nanoliposomal doxorubicin in a xenograft model of colorectal cancer.
Lin J; Yu Y; Shigdar S; Fang DZ; Du JR; Wei MQ; Danks A; Liu K; Duan W
PLoS One; 2012; 7(11):e49277. PubMed ID: 23145140
[TBL] [Abstract][Full Text] [Related]
18. Near infra-red laser mediated photothermal and antitumor efficacy of doxorubicin conjugated gold nanorods with reduced cardiotoxicity in swiss albino mice.
Arunkumar P; Raju B; Vasantharaja R; Vijayaraghavan S; Preetham Kumar B; Jeganathan K; Premkumar K
Nanomedicine; 2015 Aug; 11(6):1435-44. PubMed ID: 25881739
[TBL] [Abstract][Full Text] [Related]
19. Protective effects of mito-TEMPO against doxorubicin cardiotoxicity in mice.
Rocha VC; França LS; de Araújo CF; Ng AM; de Andrade CM; Andrade AC; Santos Ede S; Borges-Silva Mda C; Macambira SG; Noronha-Dutra AA; Pontes-de-Carvalho LC
Cancer Chemother Pharmacol; 2016 Mar; 77(3):659-62. PubMed ID: 26712129
[TBL] [Abstract][Full Text] [Related]
20. Cardioprotective Effect of Phase 3 Clinical Anticancer Agent, RRx-001, in Doxorubicin-Induced Acute Cardiotoxicity in Mice.
Oronsky B; Ao-Ieong ESY; Yalcin O; Carter CA; Cabrales P
Mol Pharm; 2019 Jul; 16(7):2929-2934. PubMed ID: 31038318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
